Search results

TNU:s study on ALS together with Australian collaborators on Lund university's top news today. Åsa Petersén, Sanaz Gabery and collaborators in Australia have, for the first time, shown changes in hypothalamic neurons regulating metabolism, sleep and emotions in ALS patients. Since long, researchers have assumed that changes in metabolism are affecting the progress of the disease. Identification of

https://www.huntington-research.lu.se/article/new-publication-als-tnu-and-australian-collaborators - 2025-12-13

TNU published a new paper on early changes in the limbic system in Huntington disease together with international collaborators in Acta Neuropathologica, August 26, 2021. Link to article (opens in a new window): Early white matter pathology in the fornix of the limbic system in Huntington disease Link to Lund University webpage for news article on the the results (in Swedish): Känslohjärnan – en n

https://www.huntington-research.lu.se/article/important-paper-huntington-disease-gabery-et-al-acta-neuropathologica-2021 - 2025-12-13

Petersén and Gabery give talks about research at the National Huntington Meeting October 13, 2021. It is a digital meeting where you can see the talks at the home page of the Swedish patient organisation RHS:  https://huntington.se/13-oktober-valkomna-pa-nationellt-mote-kring-huntingtons-sjukdom/ (Opens a new window)  

https://www.huntington-research.lu.se/article/petersen-and-gabery-give-talks-about-research-national-huntington-meeting-october-13-202 - 2025-12-13

Petersén gives talks about research and clinical care for Huntington disease to young adults in HD families at a conference in Gothenburg October 21-24, 2021. See homepage of the patient organization Swedish Huntington Association (Riksförbundet för Huntingtons sjukdom) for more information:  Link to Swedish Huntington Association's webpage (opens in a new window)

https://www.huntington-research.lu.se/article/petersen-gives-talks-conference-young-people-hd - 2025-12-13

On 11-12 November 2021 the SWEMODIS annual meeting on Parkinson’s disease and other Movement Disorders took place in Stockholm, where Åsa Petersén gave a talk on Huntington's disease. SWEMODIS webpage (opens in a new window)

https://www.huntington-research.lu.se/article/petersen-gave-talk-annual-swemodis-meeting - 2025-12-13

Huntington disease is the topic of today’s episode of the radio program Kropp & Själ, Body & Mind, on the Swedish public service radio. The dilemma of genetic testing is one of the aspects of the disease discussed in the program, where Åsa Petersén is a guest. You can access today’s episode on Sveriges Radio’s website: https://sverigesradio.se/avsnitt/huntingtons-sjukdom-den-felande-genen (in Swed

https://www.huntington-research.lu.se/article/about-huntington-disease-swedish-radio - 2025-12-13

Petersén (PI) and Gabery (co-PI) received a research grant of 1.2 MSEK from the Swedish Brain Foundation (Hjärnfonden) for a project on novel mechanisms of disease and a potential future therapy for HD. Link to the Swedish Brain Foundation's webpage  

https://www.huntington-research.lu.se/article/research-grant-swedish-brain-foundation - 2025-12-13

Petersén (PI) received a research grant of 6 MSEK from the Swedish Research Council (Vetenskapsrådet) for 2023-2026 for a project on novel cellular and molecular mechanisms in the limbic system for psychiatric symptoms in Huntington disease. 

https://www.huntington-research.lu.se/article/research-grant-swedish-research-council - 2025-12-13

Åsa Petersén has been elected member of the executive committee for the European Huntington Disease Network (EHDN). The EHDN is a nonprofit research network committed to advancing research, facilitating the conduct of clinical trials, and improving clinical care in HD. Through the EHDN a platform has been created such that basic scientists, clinicians, patients and families can collaborate on acad

https://www.huntington-research.lu.se/article/asa-petersen-elected-member-executive-committee-european-huntington-disease-network-ehdn - 2025-12-13

Through her work, Professor Cenci Nilsson has developed preclinical models mimicking the symptoms of Parkinson’s disease and L-DOPA-induced dyskinesia, exploiting these models to discover disease mechanisms and new therapeutic approaches. With this motivation, MultiPark’s coordinator was awarded the 2022 Bengt Falck Prize in Neuroscience. In this extensive interview, Angela Cenci Nilsson shares he

https://www.multipark.lu.se/article/multiparks-coordinator-awarded-bengt-falck-prize-neuroscience - 2025-12-13

Imaging methods are valuable tools for understanding neurodegenerative diseases and monitoring the therapeutic effects of new treatments. That is why MultiPark researchers with expertise in clinical imaging gather across research groups. Clinical imaging methods is a new special interest group (SIG) addressing scientific and technological needs to apply these methods in research. Nicola Spotorno t

https://www.multipark.lu.se/article/clinical-imaging-methods-special-interest-group - 2025-12-13

People with Parkinson´s disease (PD) often develop abnormal involuntary movements (dyskinesias) during the course of their treatment with dopaminomimetic drugs.  In this new collaborative project, Angela Cenci Nilsson (Lund), Mattias Rickhag (Copenhagen) and Gilad Silberberg (Stockholm) will unravel the connections between dyskinesia and changes in the way the cerebral cortex and the striatum proc

https://www.multipark.lu.se/article/new-collaborative-project-tackles-previously-unknown-mechanisms-parkinsons-dyskinesias - 2025-12-13

Martino Avallone spent the past four years developing tools for mapping gene expression and proteins in the brain to investigate basic biological questions and to elucidate the molecular mysteries contributing to Parkinson’s disease. On 29 September, he defends his thesis work done in the Molecular Neuromodulation research group. Here, he explains the impact these tools will hopefully have in scie

https://www.multipark.lu.se/article/genetic-tools-studying-parkinsons-disease-phd-interview-martino-avallone - 2025-12-13

Megg Garcia-Ryde’s thesis sheds light on the early pathological processes in Alzheimer’s disease and the interplay between neurons and microglia as the disease evolves. October 10, she defends her thesis. Now, she gives her perspectives from a close collaboration between two of MultiPark’s experimental research groups and how she brings together the expertise of both groups. Tell us about your res

https://www.multipark.lu.se/article/neuroimmune-crosstalk-early-alzheimers-disease-phd-interview-megg-garcia-ryde - 2025-12-13

In today's scientific world, microscopic images have become a powerful resource for research. With access to advanced microscopes, researchers can now create unique images of structures and objects. Beautiful and captivating images that can also convey complex context to a wider audience. Microscopic images offer a clear advantage over purely quantitative measurements: they allow us to see the str

https://www.multipark.lu.se/article/making-invisible-visible-magic-microscopic-images - 2025-12-13

Is it possible that a single biomarker can detect all types of diseases related to dopamine deficiency in the brain? Yes, that's what a research group in Lund is discovering. "We have observed that an enzyme in cerebrospinal fluid and in blood is a useful marker for identifying all types of Parkinson's-related diseases with high accuracy," says Oskar Hansson, who led the study. The marker in quest

https://www.multipark.lu.se/article/new-blood-marker-can-identify-parkinsonian-diseases - 2025-12-13

Jana Rájová’s research turns light on gene expression in different parts of the brain affected by Parkinson’s disease. October 23, she defends her thesis in the Molecular Neuromodulation research group. In this interview, she tells about how it has been to combine wet and dry lab work and about the technical advances in the field. Tell us about your research! “Throughout my Ph.D. journey, my resea

https://www.multipark.lu.se/article/gene-expression-parkinsons-disease-phd-interview-jana-rajova - 2025-12-13

A recent publication by MultiPark researchers at Lund University’s Lund Stem Cell Center gives a closer look at the making of a novel stem cell therapy for Parkinson’s Disease, STEM-PD, which has been approved for a Phase I/IIa clinical trial in Europe. Parkinson's Disease is a neurodegenerative disorder that affects almost 8 million people worldwide, causing movement difficulties due to the loss

https://www.multipark.lu.se/article/closer-look-making-novel-stem-cell-therapy-parkinsons-disease - 2025-12-13

Sweden has made significant strategic investments into the national infrastructure MAX IV, with world-unique instruments usable across disciplines. One emerging area is within medical sciences. MultiPark researchers now gather across research groups to facilitate the usage of these state-of-the-art techniques available just around the corner. MAXIV for high-resolution, sub-cellular X-ray measureme

https://www.multipark.lu.se/article/maxiv-high-resolution-sub-cellular-x-ray-measurements-special-interest-group - 2025-12-13

The human brain is an incredibly intricate organ that regulates everything from our motor skills to our memories. But how did it evolve into the complex structure we see today? Researchers at Lund University offer new insights in their latest study, published in Science Advances, detailing how a specific group of genetic elements have influenced the development of the human brain over time. Hidden

https://www.multipark.lu.se/article/how-mobile-dna-shapes-human-brain - 2025-12-13